Skip to content

Bioequivalency study of two different Metformin formulations

Comparative bioequivalence study of two different Metformin 500mg formulations (Aburaihan Pharmaceutical Company & reference) in 24 Iranian volunteers

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20111107008022N6
Enrollment
24
Registered
2020-04-04
Start date
2020-01-31
Completion date
Unknown
Last updated
2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health and normal volunteers.

Interventions

Intervention 1: Single dose of Glucophage 500 mg tablet manufactured by Merck Pharmaceutical company in 24 healthy volunteers. Intervention 2: Control group: Single dose of Metformin 500 mg tablet ma

Sponsors

Abureihan Pharmaceutical Company
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 24 healthy male and female volunteers will participate in this study. Aged 18 to 45 years based on laboratory safety tests, no history of diseases affecting drug pharmacokinetic processes lack of any chronic or acute medication at least 1 week before the start of the study adherence to the criteria on the basis of moral obligation and signed an informed consent actual weight (TBW) in the range of 20% IBW

Exclusion criteria

Exclusion criteria: Subject showed clinically relevant deviations from normal in physical examination. Subject had undergone surgery of the gastro-intestinal tract Subject had donated a unit of blood or participated in another clinical trial, within the last three months before the first treatment Subject had a history of alcohol abuse or smokes more than 10 cigarettes per day. Use any medication within 14 days before the first treatment. A history of allergic to biguanides

Design outcomes

Primary

MeasureTime frame
Drug plasma concentration. Timepoint: blood samples were collected at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h following drug administration. Method of measurement: Using HPLC instrument.

Secondary

MeasureTime frame
Pharmacokinetic parameters: Half-life, Cmax The peak plasma concentration of a drug after administration, The volume of distribution, and Clearance. Timepoint: 0; 0.5; 1.0; 2.0; 3.0; 4.0; 4.5; 5.0; 5.5; 6.0; 6.5; 7.0; 8.0; 9.0; 10.0; 12.0; 16.0; 20.0; 24.0; 30.0 and 36 hours post-dose. Method of measurement: Drug analysis in plasma using a chromatographic apparatus and calculating pharmacokinetic parameters using pharmacokinetic models.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Katayoun Derakhshandeh

Hamedan University of Medical Sciences

k.derakhshandeh@umsha.ac.ir+98 81 3838 1590

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026